<DOC>
	<DOC>NCT00684268</DOC>
	<brief_summary>By chance the investigators found that iv. silibinin has a potent antiviral effect against the hepatitis C virus. Based on the results of the dose finding study (published) te optima dosing schedule is explored.This study will be evaluate whether the highest active dose given for the optimal time combined with standard of care will result in a sustained virologic response (=cure of hepatitis C).</brief_summary>
	<brief_title>Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders</brief_title>
	<detailed_description>Since the publication of the first data the optimal dosing schedule is investigated</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Silybin</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>Nonresponders to full dose PEGIFN/RBV therapy Liver biopsy within the last 2 year Intolerance to one of the study drugs Coinfection with HIV/HBV</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>silibinin</keyword>
	<keyword>chronic hepatitis C</keyword>
	<keyword>peginterferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>nonresponders</keyword>
	<keyword>efficacy of iv. silibinin</keyword>
	<keyword>safety</keyword>
</DOC>